Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  DEC 01  ChemPort single article sales feature unavailable
 NEWS  3  JUN 01  CAS REGISTRY Source of Registration (SR) searching
                  enhanced on STN
 NEWS  4  JUN 26  NUTRACEUT and PHARMAML no longer updated
 NEWS  5  JUN 29  IMSCOPROFILE now reloaded monthly
 NEWS  6  JUN 29  EPFULL adds Simultaneous Left and Right Truncation
                  (SLART) to AB, MCLM, and TI fields
 NEWS  7  JUL 09  PATDPAFULL adds Simultaneous Left and Right
                  Truncation (SLART) to AB, CLM, MCLM, and TI fields
 NEWS  8  JUL 14  USGENE enhances coverage of patent sequence location
                  (PSL) data
 NEWS  9  JUL 27  CA/CAplus enhanced with new citing references
 NEWS 10  JUL 16  GBFULL adds patent backfile data to 1855
 NEWS 11  JUL 21  USGENE adds bibliographic and sequence information
 NEWS 12  JUL 28  EPFULL adds first-page images and applicant-cited
                  references
 NEWS 13  JUL 28  INPADOCDB and INPAFAMDB add Russian legal status data

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
```

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:27:20 ON 07 AUG 2009

=>
Uploading

```
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 15:27:43 ON 07 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 AUG 2009  HIGHEST RN 1173240-01-1
DICTIONARY FILE UPDATES:   6 AUG 2009  HIGHEST RN 1173240-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10591921.str
```



chain nodes :
17 18 19 20 21 22 23 25 26 27 28 38 39
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 29 33 34 35 36 37
chain bonds :
1-17 3-25 4-18 4-19 5-20 6-22 7-21 8-23 12-39 15-26 26-27 26-28 28-34 37-38
ring bonds :
1-2 1-16 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 12-29 13-14 13-29 14-15 15-16 33-34 33-37 34-35 35-36 36-37
exact/norm bonds :
1-2 1-16 1-17 2-3 3-4 3-25 4-5 4-18 4-19 5-6 5-20 6-7 6-22 7-8 7-21 8-9 8-23 9-10 10-11 11-12 12-13 12-29 12-39 13-14 13-29 14-15 15-16 15-26 26-27 26-28 28-34 33-34 33-37 34-35 35-36 36-37 37-38
isolated ring systems :
containing 1 : 33 :

G1:H,OH

G2:C,O

G3:H,Ak,CH3,Et,n-Pr

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:CLASS 39:CLASS

Stereo Bonds:

22-6 (Single Hash).
23-8 (Single Hash).
26-15 (Single Wedge).

Stereo Chiral Centers:

6 (Parity=Even)
8 (Parity=Odd)
15 (Parity=Odd)

Stereo RSS Sets:

Type=Relative (Default). 3 Nodes= 6 8 15

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,OH
G2 C,O
G3 H,Ak,Me,Et,n-Pr

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:28:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 43 TO ITERATE

100.0% PROCESSED 43 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 467 TO 1253
PROJECTED ANSWERS: 33 TO 447

L2 12 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:28:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 749 TO ITERATE

100.0% PROCESSED 749 ITERATIONS 178 ANSWERS
SEARCH TIME: 00.00.01

L3 178 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 185.88 186.10

FILE 'HCAPLUS' ENTERED AT 15:28:24 ON 07 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Aug 2009 VOL 151 ISS 7
FILE LAST UPDATED: 6 Aug 2009 (20090806/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> s l3

```
L4         789 L3

=> s l4 and p/dt
      6789111 P/DT
L5         383 L4 AND P/DT

=> s l5 and us/pc
      1963723 US/PC
L6         229 L5 AND US/PC

=> s l6 and py<=2004
     25141264 PY<=2004
L7         154 L6 AND PY<=2004

=> s l7 and epothilone
          1213 EPOTHILONE
           975 EPOTHILONES
          1558 EPOTHILONE
                (EPOTHILONE OR EPOTHILONES)
L8         151 L7 AND EPOTHILONE

=> d l8 ibib abs hitstr 1-10

L8   ANSWER 1 OF 151  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2007:203160  HCAPLUS
DOCUMENT NUMBER:         146:267903
TITLE:                   PSMA-binding aptamers and conjugates of PSMA-binding
                         aptamers for disease treatment
INVENTOR(S):             Diener, John L.; Hatala, Paul; Wagner-Whyte, Jess;
                         Wilson, Charles
PATENT ASSIGNEE(S):      USA
SOURCE:                  U.S. Pat. Appl. Publ., 113pp., Cont.-in-part of U.S.
                         Ser. No. 826,077.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  12
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     US 20070041901       A1    20070222    US 2006-370491         20060307 <--
     US 20040022727       A1    20040205    US 2003-600007         20030618 <--
     US 20040249130       A1    20041209    US 2004-826077         20040415 <--
PRIORITY APPLN. INFO.:                       US 2002-390042P     P  20020618
                                             US 2003-600007      A2 20030618
                                             US 2004-826077      A2 20040415
                                             US 2005-660514P     P  20050307
                                             US 2005-670518P     P  20050411
AB   The present invention provides stabilized, high affinity nucleic acid
     ligands to PSMA as well as conjugates of these aptamers with various
     moieties, esp, drugs or cytotoxic compds. or protein toxins.  Thus, the
     identification and preparation of novel, stable, high affinity ligands to PSMA
     using the SELEX method with 2'-O-Me substituted nucleic acids, and cell
     surface SELEX are described.  Two aptamer-vinblastine conjugates were
     tested in an in vitro cell proliferation assay.  These conjugates killed
     LNCaP cells at 10-500 nM.
```

IT 152044-54-7D, Epothilone B, aptamer conjugates
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PSMA-binding aptamers and conjugates of PSMA-binding aptamers for disease treatment)
RN 152044-54-7 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L8 ANSWER 2 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1005828 HCAPLUS
DOCUMENT NUMBER: 143:292590
TITLE: Method of producing cationic liposomes comprising a lipophilic compound
INVENTOR(S): Mundus, Carsten; Welz, Christain; Schramel, Oliver; Haas, Heinrich; Fichert, Thomas; Schulze, Brita; Peymann, Toralf; Michaelis, Uwe; Teifel, Michael; Gruber, Friedrich; Winter, Gerhard
PATENT ASSIGNEE(S): Medigene Oncology G.m.b.H., Germany
SOURCE: U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of Appl. No. PCT/EP03/06759.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050202076	A1	20050915	US 2004-18574	20041222 <--
EP 1374864	A1	20040102	EP 2002-18724	20020821 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2004002468	A1	20040108	WO 2003-EP6759	20030626 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-391245P	P 20020626
			US 2002-391246P	P 20020626
			EP 2002-18724	A 20020821
			EP 2003-4744	A 20030304
			WO 2003-EP6759	A2 20030626

AB A method for producing a cationic liposome comprising a lipophilic active compound with phys. and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposome obtainable by this method as well as pharmaceutical compns. are disclosed. Thus, liposomes contained paclitaxel 3, DOTAP-Cl 50, DOPC 47, trehalose-dihydrate 108.2, and EtOH 1.33 mol%.

IT 152044-54-7, Epothilone B
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of producing cationic liposomes comprising a lipophilic compound)

RN 152044-54-7 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



L8 ANSWER 3 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:641841 HCAPLUS
DOCUMENT NUMBER: 143:159436
TITLE: Aptamers binding to platelet-derived growth factor and their use in treatment of neoplasms dependent on the growth factor
INVENTOR(S): Grate, Dilara; Diener, John L.; Wilson, Charles; McCauley, Thomas Greene
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 104 pp., Cont.-in-part of U.S. Ser. No. 873,853.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050159351	A1	20050721	US 2004-980211	20041102 <--
US 20040180360	A1	20040916	US 2003-718833	20031121 <--
US 20040253243	A1	20041216	US 2004-762915	20040121 <--
US 20040249130	A1	20041209	US 2004-826077	20040415 <--
US 20040253679	A1	20041216	US 2004-829504	20040421 <--
US 20050124565	A1	20050609	US 2004-873853	20040621 <--
WO 2005052121	A2	20050609	WO 2004-US39137	20041122
WO 2005052121	A3	20060608		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, US
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

WO 2006050498 A2 20060511 WO 2005-US39975 20051102
WO 2006050498 A3 20070405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1807107 A2 20070718 EP 2005-824135 20051102
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU

US 20070009476 A1 20070111 US 2006-482671 20060706 <--
US 20090053138 A1 20090226 US 2008-666954 20080505 <--

PRIORITY APPLN. INFO.:

US 2002-428102P	P	20021121
US 2003-441357P	P	20030121
US 2003-463095P	P	20030415
US 2003-464179P	P	20030421
US 2003-464239P	P	20030421
US 2003-465053P	P	20030423
US 2003-465055P	P	20030423
US 2003-469628P	P	20030508
US 2003-474133P	P	20030529
US 2003-474680P	P	20030529
US 2003-486580P	P	20030711
US 2003-489810P	P	20030723
US 2003-491019P	P	20030729
US 2003-503596P	P	20030916
US 2003-512071P	P	20031017
US 2003-523935P	P	20031121
US 2003-718833	A2	20031121
US 2004-537045P	P	20040116
US 2004-537201P	P	20040116
US 2004-762915	A2	20040121
US 2004-826077	A2	20040415
US 2004-829504	A2	20040421
US 2004-873853	A2	20040621
US 2002-390042P	P	20020618
US 2003-600007	A2	20030618
US 2004-980211	A2	20041102
US 2004-632358P	P	20041130
US 2004-632609P	P	20041201
US 2005-652496P	P	20050210
US 2005-652494P	P	20050211

US 2005-667866P P 20050401
US 2005-672200P P 20050415
WO 2005-US39975 W 20051102

AB Therapeutically useful aptamer ligands for platelet-derived growth factor (PDGF) and its isoforms, PDGF receptors, vascular endothelial growth factor (VEGF), and VEGF receptor are described for use in cancer therapy. The aptamers may bind one or more of these proteins. These aptamers are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs for use as adjuvants. These aptamers were selected by SELEX. These oligonucleotides inhibited the proliferation of 3T3 cells in culture at concns. of 3 nM to >1 μM. They also inhibited PDGF-dependent chemotaxis of 3T3 cells. In a Lewis lung carcinoma model, aptamers were effective in inhibiting proliferation of implants in mice. The composition, when combined with irinotecan, improved the efficacy of the irinotecan in colon cancer xenograft models.

IT 152044-54-7, Epothilone B
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer chemotherapy with aptamers and; aptamers binding to platelet-derived growth factor and their use in treatment of neoplasms dependent on PDGF)

RN 152044-54-7 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



L8 ANSWER 4 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:572598 HCAPLUS

DOCUMENT NUMBER: 143:97209
TITLE: Synthesis of epothilones for use in pharmaceutical compositions as antitumor agents
INVENTOR(S): Danishefsky, Samuel J.; Rivkin, Alexey; Yoshimura, Fumihiko; Chou, Ting-Chao; Gabarda, Ana E.; Dong, Huajin; Wu, Kaida; Moore, Malcolm A. S.; Dorn, David
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 274 pp., Cont.-in-part of U.S. Ser. No. 435,408.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050143429	A1	20050630	US 2004-921109	20040818 <--
US 7384964	B2	20080610		
US 20040053995	A1	20040318	US 2003-402004	20030328 <--
US 6921769	B2	20050726		
US 20040053910	A1	20040318	US 2003-435408	20030509 <--
AU 2005218308	A1	20050915	AU 2005-218308	20050228
CA 2556692	A1	20050915	CA 2005-2556692	20050228
WO 2005084222	A2	20050915	WO 2005-US6051	20050228
WO 2005084222	A3	20051124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1722791	A2	20061122	EP 2005-723768	20050228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1976699	A	20070606	CN 2005-80013480	20050228
BR 2005008232	A	20070717	BR 2005-8232	20050228
JP 2007525519	T	20070906	JP 2007-500999	20050228
ZA 2005002337	A	20060927	ZA 2005-2337	20050318
MX 2006009792	A	20061116	MX 2006-9792	20060828
KR 2007100626	A	20071011	KR 2006-720063	20060927
US 20090149516	A1	20090611	US 2008-135823	20080609 <--

PRIORITY APPLN. INFO.:

US 2002-405823P	P	20020823
US 2002-408589P	P	20020906
US 2002-423129P	P	20021101
US 2003-456159P	P	20030320
US 2003-402004	A2	20030328
US 2003-435408	A2	20030509
US 2003-496741P	P	20030821
US 2004-548402P	P	20040227
US 2004-921109	A	20040818
WO 2005-US6051	W	20050228

OTHER SOURCE(S): CASREACT 143:97209; MARPAT 143:97209
GI



I II

AB Epothilone analogs, such as I [-A-B-, -C-D- = -C.tplbond.C-, -CH(R)CH(R1)-, -C(R):C(R1)-; R, R1 = H, alkyl, halogen, alkoxy, acyl, etc.; -A-B- = fused oxirane ring; -C-D- = fused cyclopropane or fused aziridine ring; R2 = aryl, heteroaryl, arylalkyl, heteroarylalkyl] are prepared as antitumor agents. The present invention also provides pharmaceutical compns. comprising compds. of formula I and provides methods of treating cancer comprising administering a compound of formula I. Thus, II was prepared via an intramol. methathesis macrocyclization synthetic sequence and showed good cell growth inhibition against various drug-resistant tumors.

IT 152044-54-7P 190370-13-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of epothilone derivs. for use in pharmaceutical compns. as antitumor agents)

RN 152044-54-7 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 190370-13-9 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1R,3S,7S,10R,11S,12S,16S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:497473 HCAPLUS
DOCUMENT NUMBER: 143:65317
TITLE: Aptamers binding to PDGF, VEGF, or other targets and their use as oncology therapeutics
INVENTOR(S): Diener, John L.; Epstein, David; Ferguson, Alicia; Grate, Dilara; Keefe, Anthony Dominic; McCauley, Thomas Greene; Preiss, Jeffrey R.; Stanton, Martin; Wilson, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 101 pp., Cont.-in-part of U.S. Ser. No. 829,504.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050124565	A1	20050609	US 2004-873853	20040621 <--
US 20040180360	A1	20040916	US 2003-718833	20031121 <--
US 20040253243	A1	20041216	US 2004-762915	20040121 <--
US 20040249130	A1	20041209	US 2004-826077	20040415 <--
US 20040253679	A1	20041216	US 2004-829504	20040421 <--
US 20050159351	A1	20050721	US 2004-980211	20041102 <--
WO 2005052121	A2	20050609	WO 2004-US39137	20041122
WO 2005052121	A3	20060608		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, US				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070009476	A1	20070111	US 2006-482671	20060706 <--
US 20090053138	A1	20090226	US 2008-666954	20080505 <--

PRIORITY APPLN. INFO.:

US 2002-428102P	P	20021121
US 2003-441357P	P	20030121
US 2003-463095P	P	20030415
US 2003-464179P	P	20030421
US 2003-464239P	P	20030421
US 2003-465053P	P	20030423
US 2003-465055P	P	20030423
US 2003-469628P	P	20030508
US 2003-474133P	P	20030529
US 2003-474680P	P	20030529
US 2003-486580P	P	20030711
US 2003-489810P	P	20030723
US 2003-491019P	P	20030729

US 2003-503596P	P	20030916
US 2003-512071P	P	20031017
US 2003-523935P	P	20031121
US 2003-718833	A2	20031121
US 2004-537045P	P	20040116
US 2004-537201P	P	20040116
US 2004-762915	A2	20040121
US 2004-826077	A2	20040415
US 2004-829504	A2	20040421
US 2002-390042P	P	20020618
US 2003-600007	A2	20030618
US 2004-873853	A2	20040621
US 2004-980211	A2	20041102
US 2004-632358P	P	20041130
US 2004-632609P	P	20041201
US 2005-652496P	P	20050210
US 2005-652494P	P	20050211
US 2005-667866P	P	20050401
US 2005-672200P	P	20050415
WO 2005-US39975	W	20051102

AB Materials and methods are provided for producing and using aptamers useful as oncol. therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, and VEGF or any combination thereof with great affinity and specificity. The compns. of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto. Thus, a composition comprising three PDGF-binding aptamers connected via hexaethylene glycol bridges and conjugated to PEG at the 5'-terminus was prepared This composition exhibited superior pharmacokinetics to one not conjugated to PEG. The composition, when combined with irinotecan, improved the efficacy of the irinotecan in colon cancer xenograft models.

IT 152044-54-7, Epothilone B
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aptamers and; aptamers binding to PDGF, VEGF, or other targets and their use as oncol. therapeutics)

RN 152044-54-7 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



L8 ANSWER 6 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1080882 HCAPLUS
DOCUMENT NUMBER: 142:38062
TITLE: Preparation of protected 5,7-dihydroxy-4,4-dimethyl-3-oxoheptanoic acid ester derivatives and intermediates thereof for synthesizing epothilones and derivatives
INVENTOR(S): Westermann, Juergen; Platzek, Johannes; Petrov, Orlin
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108697	A1	20041216	WO 2004-EP6057	20040605 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10326195	A1	20041223	DE 2003-10326195	20030607 <--

EP 1631563 A1 20060308 EP 2004-739609 20040605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
JP 2006527180 T 20061130 JP 2006-508280 20040605
US 20080015366 A1 20080117 US 2007-559389 20070316 <--
PRIORITY APPLN. INFO.: DE 2003-10326195 A 20030607
WO 2004-EP6057 W 20040605
OTHER SOURCE(S): MARPAT 142:38062
GI



I



III

AB The present invention discloses methods for preparation of novel protected 5,7-dihydroxy-4,4-dimethyl-3-oxoheptanoic acid ester derivs., such as I [R1, R2 = hydroxyl protecting group; R1R2 = isopropylidne; R3 = alkyl; R4 = allyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkenyl, alkoxyalkynyl, arylalkyl, etc.], and intermediates thereof for the synthesis of epothilones and epothilone derivs. Thus, 3-[(4S)-2,2-dimethyl-1,3-dioxan-4-yl]-3-methyl-butan-2-one, [obtained by the reaction of 3(S)-(3,5)-acetonedimethylketal-2,2-dimethyl-pentan-nitrile and methyllithium-lithiumbromide-complex], was treated with diallylcarbonate to afford (4S)-2,2-dimethyl-[1,3]-dioxan-4-yl-4-methyl-3-oxo-pentanoic acid allyl ester (II). II was reacted with terakistriphenylphosphinepalladium to provide (4S)-4-(2-methyl-3-oxo-hept-6-ene-2-yl)-2,2-dimethyl-[1,3]-dioxane, which was hydrogenated in presence of palladium-carbon to afford (4S)-4-(2-methyl-3-oxo-heptane-2-yl)-2,2-dimethyl-[1,3]-dioxane (III).

IT 152044-53-6DP, Epothilone A, derivs.
RL: PNU (Preparation, unclassified); PREP (Preparation)
(preparation of protected 5,7-dihydroxy-4,4-dimethyl-3-oxoheptanoic acid esters and intermediates thereof for synthesizing epothilones and derivs.)

RN 152044-53-6 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1080626 HCAPLUS
DOCUMENT NUMBER: 142:49205
TITLE: Stabilized aptamers to growth factors and their receptors for use in the treatment of solid tumors
INVENTOR(S): Epstein, David; Grate, Dilara; Stanton, Martin; Diener, John L.; Wilson, Charles; McCauley, Thomas; DeSouza, Errol
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 96 pp., Cont.-in-part of U.S. Ser. No. 762,915.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20040253679	A1	20041216	US 2004-829504		20040421	<--
US 20040180360	A1	20040916	US 2003-718833		20031121	<--
US 20040253243	A1	20041216	US 2004-762915		20040121	<--
US 20050124565	A1	20050609	US 2004-873853		20040621	<--
US 20050159351	A1	20050721	US 2004-980211		20041102	<--
US 20070009476	A1	20070111	US 2006-482671		20060706	<--
US 20090053138	A1	20090226	US 2008-666954		20080505	<--
PRIORITY APPLN. INFO.:			US 2002-428102P	P	20021121	
			US 2003-441357P	P	20030121	
			US 2003-463095P	P	20030415	

US 2003-464179P	P	20030421
US 2003-464239P	P	20030421
US 2003-465053P	P	20030423
US 2003-465055P	P	20030423
US 2003-469628P	P	20030508
US 2003-474133P	P	20030529
US 2003-474680P	P	20030529
US 2003-486580P	P	20030711
US 2003-489810P	P	20030723
US 2003-491019P	P	20030729
US 2003-503596P	P	20030916
US 2003-512071P	P	20031017
US 2003-718833	A2	20031121
US 2004-537045P	P	20040116
US 2004-537201P	P	20040116
US 2004-762915	A2	20040121
US 2003-523935P	P	20031121
US 2004-826077	A2	20040415
US 2004-829504	A2	20040421
US 2004-873853	A2	20040621
US 2004-980211	A2	20041102
US 2004-632358P	P	20041130
US 2004-632609P	P	20041201
US 2005-652496P	P	20050210
US 2005-652494P	P	20050211
US 2005-667866P	P	20050401
US 2005-672200P	P	20050415
WO 2005-US39975	W	20051102

AB Aptamers that bind specifically to platelet-derived growth factor, vascular endothelial growth factor, their receptors and isoforms of the growth factors are described for use in the treatment of solid tumors dependent on these growth factors. They can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. The aptamers are modified, e.g. by using modified backbones or conjugation with polyethylene glycol, to improve in vivo stability. Aptamers with one or more immunostimulant CpG motifs are also described. Bivalent aptamers binding one of these targets and another growth- or apoptosis-regulating are also described.

IT 152044-54-7, Epothilone B
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer therapy with aptamers and; stabilized aptamers to growth factors and their receptors for use in treatment of solid tumors)

RN 152044-54-7 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L8 ANSWER 8 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1060832 HCAPLUS
DOCUMENT NUMBER: 142:43740
TITLE: Aptamer-toxin molecules and methods for using same
INVENTOR(S): Stanton, Martin; Kurz, Markus; Wilson, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 600,007.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040249130	A1	20041209	US 2004-826077	20040415 <--
US 20040022727	A1	20040205	US 2003-600007	20030618 <--
AU 2004232848	A2	20041104	AU 2004-232848	20040421 <--
AU 2004232848	A1	20041104		
CA 2523260	A1	20041104	CA 2004-2523260	20040421 <--
WO 2004094614	A2	20041104	WO 2004-US12670	20040421 <--
WO 2004094614	A3	20060727		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, US

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1620547 A2 20060201 EP 2004-760163 20040421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2007525177 T 20070906 JP 2006-513287 20040421
US 20050124565 A1 20050609 US 2004-873853 20040621 <--
US 20050159351 A1 20050721 US 2004-980211 20041102 <--
WO 2005116255 A2 20051208 WO 2005-US12797 20050415
WO 2005116255 A3 20060413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, US
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1756318 A2 20070228 EP 2005-778410 20050415
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

US 20070041901 A1 20070222 US 2006-370491 20060307 <--
US 20090053138 A1 20090226 US 2008-666954 20080505 <--

PRIORITY APPLN. INFO.:

US 2002-390042P	P	20020618
US 2003-600007	A2	20030618
US 2002-428102P	P	20021121
US 2003-441357P	P	20030121
US 2003-463095P	P	20030415
US 2003-464179P	P	20030421
US 2003-464239P	P	20030421
US 2003-465053P	P	20030423
US 2003-465055P	P	20030423
US 2003-469628P	P	20030508
US 2003-474133P	P	20030529
US 2003-474680P	P	20030529
US 2003-486580P	P	20030711
US 2003-489810P	P	20030723
US 2003-491019P	P	20030729
US 2003-503596P	P	20030916
US 2003-512071P	P	20031017
US 2003-523935P	P	20031121
US 2003-718833	A	20031121
US 2004-537045P	P	20040116
US 2004-537201P	P	20040116
US 2004-762915	A	20040121
US 2004-826077	A	20040415
US 2004-829504	A2	20040421
WO 2004-US12670	W	20040421
US 2004-873853	A2	20040621
US 2004-980211	A2	20041102

US 2004-632358P	P	20041130
US 2004-632609P	P	20041201
US 2005-652496P	P	20050210
US 2005-652494P	P	20050211
US 2005-660514P	P	20050307
US 2005-667866P	P	20050401
US 2005-670518P	P	20050411
US 2005-672200P	P	20050415
WO 2005-US12797	W	20050415
WO 2005-US39975	W	20051102

AB Materials and methods are provided to prepare therapeutic conjugates for the treatment of proliferative diseases. The therapeutic conjugates of the invention comprise a targeting moiety conjugated to a therapeutic moiety. The therapeutic moiety of the conjugates of the present invention have a cytotoxic effect and are useful in the treatment of proliferative diseases.

IT 152044-54-7D, Epothilone B, aptamer conjugates
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aptamer-toxin conjugates for targeted treatment of proliferative diseases)

RN 152044-54-7 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



L8 ANSWER 9 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1036893 HCAPLUS
DOCUMENT NUMBER: 142:697
TITLE: Combination of histone deacetylase inhibitors with

chemotherapeutic agents
INVENTOR(S): Atadja, Peter Wisdom; Remiszewski, Stacy William; Trogani, Nancy
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103358	A2	20041202	WO 2004-EP5433	20040519 <--
WO 2004103358	A3	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004241729	A1	20041202	AU 2004-241729	20040519 <--
CA 2526908	A1	20041202	CA 2004-2526908	20040519 <--
EP 1628651	A2	20060301	EP 2004-733798	20040519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1791396	A	20060621	CN 2004-80013238	20040519
BR 2004010648	A	20060704	BR 2004-10648	20040519
JP 2006528952	T	20061228	JP 2006-529883	20040519
MX 2005012464	A	20060130	MX 2005-12464	20051118
IN 2005CN03082	A	20070831	IN 2005-CN3082	20051121
US 20070123580	A1	20070531	US 2007-557162	20070109 <--

PRIORITY APPLN. INFO.: US 2003-472161P P 20030521
WO 2004-EP5433 W 20040519

OTHER SOURCE(S): MARPAT 142:697

AB The invention relates to a combination which comprises (a) one or more chemotherapeutic agents and (b) a histone deacetylase inhibitor ('HDAI') for simultaneous, concurrent, sep. or sequential use, especially for use in the treatment of proliferative diseases including pre-malignant lesions (e.g. colon polyps) and malignancies, both solid and undifferentiated or other proliferative diseases in a mammal, particularly a human. The invention also relates to pharmaceutical compns. comprising such a combination and to a method of preventing or treating proliferative diseases including pre-malignant lesions (e.g. colon polyps) and malignancies, both solid and undifferentiated or other proliferative diseases, in a mammal, particularly a human, with such a combination. The present invention further also relates to a com. package or product comprising such a combination.

IT 152044-54-7, Epothilone B
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of histone deacetylase inhibitors with chemotherapeutic

agents)
RN 152044-54-7 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:960045 HCAPLUS
DOCUMENT NUMBER: 141:384396
TITLE: Bone-localizing radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
INVENTOR(S): Braendle, Edgar; Hausman, Diana
PATENT ASSIGNEE(S): Schering Ag, Germany
SOURCE: Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1475105	A1	20041110	EP 2003-11721	20030523 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
WO 2004098651 A2 20041118 WO 2004-EP4434 20040427 <--
WO 2004098651 A3 20050407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1622650 A2 20060208 EP 2004-739109 20040427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
JP 2006525965 T 20061116 JP 2006-505288 20040427
US 20070092440 A1 20070426 US 2006-556163 20061121 <--
PRIORITY APPLN. INFO.: US 2003-469007P P 20030509
EP 2003-11721 A 20030523
WO 2004-EP4434 W 20040427

AB The present invention relates to a method for the improved treatment of a cancerous disease in a patient and/or for the palliation of pain associated with cancer diseases, comprising the administration of a tubulin interacting compound in combination with a bone-localizing radiopharmaceutical to the patient in an effective amount that will not cause any substantial ablation of the bone marrow. In particular, the cancerous disease is selected from the group of cancer diseases, comprising multiple myeloma, leukemia, lymphoma, breast cancer, prostate cancer, gynecol. cancer, gastric cancer ovarian cancer, lung cancer and/or renal cell carcinoma. In a preferred embodiment, the bone-localizing radiopharmaceutical is samarium Sm 153 lexidronam (Quadramet) and the tubulin-interacting compound is docetaxel.

IT 152044-53-6, Epothilone A 152044-54-7, Epothilone B
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer radiotherapy with combination of bone-localizing radiopharmaceutical and tubulin-interacting compound)

RN 152044-53-6 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 152044-54-7 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l8 ibib abs hitstr 40-50

L8 ANSWER 40 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:931114 HCAPLUS
DOCUMENT NUMBER: 139:395751
TITLE: Preparation of C-21 modified epothilone derivatives for use in pharmaceutical compositions for the treatment of cancer
INVENTOR(S): Lee, Francis Y. F.; Haby, Thomas A.; Naringrekar, Vijay H.; Raghavan, Krishnaswamy S.; Franchini, Miriam K.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003096975	A2	20031127	WO 2003-US15097	20030513 <--
WO 2003096975	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003234545	A1	20031202	AU 2003-234545	20030513 <--
US 20040053978	A1	20040318	US 2003-437103	20030513 <--
US 7053069	B2	20060530		
EP 1505969	A2	20050216	EP 2003-728885	20030513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-380634P P 20020515
WO 2003-US15097 W 20030513

OTHER SOURCE(S): MARPAT 139:395751
GI



I

AB C-21 modified epothilones, such as I [R = NH2, OH, SH, alkylamino, alkoxy, alkylthio, etc.], were prepared for therapeutic use as antitumor agents. Thus, 21-aminoepothilone B I (R = NH2) was prepared by reaction of epothilone F I (R = OH) with diphenylphosphoryl azide in THF under argon to give 21-azidoepothilone B I (R = N3) in 91% yield and subsequent hydrogenation of the azide using Lindlar catalyst in EtOH and an H2 atmosphere to give the target amine in 81% yield. The compns. are stable and readily prepared for administration by dissoln. in aqueous vehicles suitable for i.v. administration. A process for formulating C-21 modified epothilone derivs. for oral and parenteral administration was disclosed.

IT 152044-54-7, Epothilone B
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of C-21 modified epothilone derivs. for use in pharmaceutical compns. for treatment of cancer)

RN 152044-54-7 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



IT 219990-27-9P, Epothilone B N-oxide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of C-21 modified epothilone derivs. for use in pharmaceutical compns. for treatment of cancer)
RN 219990-27-9 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-3-oxido-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 41 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:913055 HCAPLUS
DOCUMENT NUMBER: 139:399770
TITLE: Medical goods comprising heparin or chitosan-based hemocompatible coating
INVENTOR(S): Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato
PATENT ASSIGNEE(S): Hemoteq G.m.b.H., Germany
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094990	A1	20031120	WO 2003-DE1253	20030415 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10221055	A1	20031127	DE 2002-10221055	20020510	<--
DE 10221055	B4	20071025			
DE 10261986	A1	20040318	DE 2002-10261986	20020510	<--
DE 10261986	B4	20080131			
AU 2003240391	A1	20031111	AU 2003-240391	20030415	<--
AU 2003240391	B2	20070517			
CA 2484269	A1	20031120	CA 2003-2484269	20030415	<--
CN 1543362	A	20041103	CN 2003-800770	20030415	<--
CN 1318103	C	20070530			
EP 1501565	A1	20050202	EP 2003-729829	20030415	
EP 1501565	B1	20061102			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003011446	A	20050315	BR 2003-11446	20030415	
CN 1665554	A	20050907	CN 2003-815926	20030415	
JP 2005534724	T	20051117	JP 2004-503070	20030415	
AT 344064	T	20061115	AT 2003-729829	20030415	
ES 2276065	T3	20070616	ES 2003-729829	20030415	
NZ 536331	A	20070831	NZ 2003-536331	20030415	
AT 404232	T	20080815	AT 2003-749833	20030415	
ES 2321082	T3	20090602	ES 2003-749833	20030415	
IN 2004MN00606	A	20050218	IN 2004-MN606	20041028	
ZA 2004008791	A	20050527	ZA 2004-8791	20041028	
ZA 2004008757	A	20050531	ZA 2004-8757	20041028	
US 20050176678	A1	20050811	US 2004-513982	20041108	<--
KR 859995	B1	20080925	KR 2004-718023	20041108	
MX 2004011112	A	20050714	MX 2004-11112	20041109	
IN 2005MN01451	A	20070706	IN 2005-MN1451	20051230	

PRIORITY APPLN. INFO.:

US 2002-378676P	P	20020509
DE 2002-10221055	A	20020510
WO 2003-DE1253	W	20030415
IN 2004-MN606	A3	20041028

AB The invention relates to oligo- and polysaccharides containing the sugar structural element N-acylglucosamine or N-acylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and chitosan. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacetylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the animals were anesthetized and the artery segments removed for histomorphometric anal.

IT 152044-53-6, Epothilone A 152044-54-7, Epothilone B
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical goods comprising a heparin-based hemocompatible coating)

RN 152044-53-6 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione,
7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-
thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 152044-54-7 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione,
7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-
thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 42 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:892609 HCAPLUS
DOCUMENT NUMBER: 139:358748
TITLE: Epothilone derivatives for the treatment of hepatoma and other cancers
INVENTOR(S): Rothermel, John David
PATENT ASSIGNEE(S): Novartis A-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092683	A1	20031113	WO 2003-EP4581	20030430 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2483826	A1	20031113	CA 2003-2483826	20030430 <--
AU 2003227702	A1	20031117	AU 2003-227702	20030430 <--

AU 2003227702	B2	20070726			
BR 2003009711	A	20050209	BR 2003-9711		20030430
EP 1503756	A1	20050209	EP 2003-725129		20030430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1649585	A	20050803	CN 2003-809770		20030430
JP 2005528414	T	20050922	JP 2004-500867		20030430
NZ 536178	A	20071026	NZ 2003-536178		20030430
RU 2358730	C2	20090620	RU 2004-135307		20030430
ZA 2004008492	A	20060927	ZA 2004-8492		20041020
IN 2004CN02466	A	20070831	IN 2004-CN2466		20041029
MX 2004010853	A	20050214	MX 2004-10853		20041101
NO 2004005249	A	20050126	NO 2004-5249		20041130
US 20050282873	A1	20051222	US 2005-512504		20050711 <--
IN 2007CN05291	A	20080627	IN 2007-CN5291		20071121
US 20080161369	A1	20080703	US 2008-46017		20080311 <--
PRIORITY APPLN. INFO.:			US 2002-377063P	P	20020501
			WO 2003-EP4581	W	20030430
			IN 2004-CN2466	A3	20041029
			US 2005-512504	A3	20050711

OTHER SOURCE(S): MARPAT 139:358748

GI



I

AB The invention provides a method for treating a warm-blooded animal, especially a human, having a cancer selected from hepatoma; primary Fallopian tube cancer; primary peritoneal cancer; breast cancer progressing after treatment with hormonal agents or radiotherapy; renal cell carcinoma progressing after treatment with a cytokine, radiotherapy, and/or nephrectomy; melanoma progressing after radiotherapy; prostate cancer progressing after orchiectomy, ovarian cancer progressing after treatment with a platinum compound or radiotherapy; and colorectal cancer progressing after radiotherapy and/or treatment with oxaliplatin or irinotecan; and metastasis thereof, comprising administering to the animal a therapeutically effective amount of an epothilone derivative I [A = O, NRN (RN = H, lower alkyl); R = H, lower alkyl; Z = O, bond], or a pharmaceutically acceptable salt thereof.

IT 152044-54-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epothilone derivs. for treatment of hepatoma and other

cancers)
RN 152044-54-7 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 43 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:757689 HCAPLUS
DOCUMENT NUMBER: 139:276755
TITLE: Preparation of epothilone derivatives for therapeutic use as anticancer agents
INVENTOR(S): Regueiro-Ren, Alicia; Kim, Soong-Hoon
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078411	A1	20030925	WO 2003-US7584	20030311 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003218110	A1	20030929	AU 2003-218110	20030311	<--
US 20030191089	A1	20031009	US 2003-386072	20030311	<--
US 6719540	B2	20040413			
EP 1483251	A1	20041208	EP 2003-714096	20030311	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-363441P	P	20020312
	WO 2003-US7584	W	20030311

OTHER SOURCE(S): MARPAT 139:276755
GI



AB Epothilone derivs., such as I [M = bond, O, NR9, CR10R11; X = O, NH; R1-R4 = H, alkyl; R5 = H, alkyl, cyano; R6 = H, alkyl, aryl, heterocyclyl; R9-R11 = H, OH, alkyl, alkoxy, aryl, cycloalkyl, heterocyclyl], pharmaceutically acceptable salts, solvates or hydrate thereof, were prepared for use as antitumor agents. Thus, epothilone derivative II was prepared from 2,3-dehydro epothilone A, via silylation of hydroxyl group, potassium cyanide addition, followed by deprotection. The prepared epothilone derivs. were assayed in vitro for their effect on tubulin polymerization and for cytotoxicity against HCT-116 human colon carcinoma cells. Therapeutic compns. containing I or in combination with other therapeutic agents useful in the treatment of cancer or other proliferative diseases are also claimed.

IT 476623-89-9P 476623-90-2P 476623-91-3P
476623-92-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of epothilone derivs. for therapeutic use as anticancer agents)

RN 476623-89-9 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-7-carbonitrile, 11-hydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-5,9-dioxo-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 476623-90-2 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-7-carbonitrile, 11-hydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-5,9-dioxo-, (1S,3S,7R,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 476623-91-3 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-7-carbonitrile, 11-hydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-5,9-dioxo-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 476623-92-4 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-7-carbonitrile, 11-hydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-5,9-dioxo-, (1S,3S,7R,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 44 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:757513 HCAPLUS
DOCUMENT NUMBER: 139:276754
TITLE: Preparation of C12-cyano epothilone derivatives with antitumor activity
INVENTOR(S): Vite, Gregory D.; Regueiro-Ren, Alicia
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077903	A1	20030925	WO 2003-US7576	20030311 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003218107	A1	20030929	AU 2003-218107		20030311 <--
US 20030186965	A1	20031002	US 2003-386059		20030311 <--
US 7211593	B2	20070501			
PRIORITY APPLN. INFO.:			US 2002-363703P	P	20020312
			WO 2003-US7576	W	20030311

OTHER SOURCE(S): MARPAT 139:276754
GI



I



II

AB Epothilone derivs. of formula I [R1-R5 = H, alkyl; R6 = H, alkyl, aryl, cycloalkyl, heterocyclo; X = H; Y = OH; XY = bond] are prepared Also included are therapeutic compns. containing the compds. of formula I as active ingredients, alone or in combination with other therapeutic agents useful in the treatment of cancer or other proliferative diseases. Thus, II was prepared in several steps from epothilone A. The EC0.01 of the prepared compds. was 0.01 to 1000 μM in in vitro tubulin polymerization assay.

IT 604772-08-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of C12-cyano epothilone derivs. with antitumor activity)

RN 604772-08-9 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-16-carbonitrile, 7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-3-oxido-4-thiazolyl)ethenyl]-5,9-dioxo-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 476623-94-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of C12-cyano epothilone derivs. with antitumor activity)

RN 476623-94-6 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-16-carbonitrile, 7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-5,9-dioxo-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 152044-53-6, Epothilone A
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of C12-cyano epothilone derivs. with antitumor activity)
RN 152044-53-6 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 45 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:757486 HCAPLUS
DOCUMENT NUMBER: 139:277113
TITLE: Synthesis of atorvastatin and epothilone synthons via 2-deoxyribose-5-phosphate aldolase-catalyzed asymmetric aldol condensation of aldehydes
INVENTOR(S): Wong, Chi-huey; Liu, Junjie; De Santis, Grace; Burk, Mark
PATENT ASSIGNEE(S): The Scripps Research Institute, USA; Diversa Corporation
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077868	A2	20030925	WO 2003-US7982	20030314 <--
WO 2003077868	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2479247	A1	20030925	CA 2003-2479247	20030314	<--
AU 2003225810	A1	20030929	AU 2003-225810	20030314	<--
US 20030232416	A1	20031218	US 2003-390544	20030314	<--
EP 1485498	A2	20041215	EP 2003-744689	20030314	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005520510	T	20050714	JP 2003-575922	20030314	
US 20070015260	A1	20070118	US 2006-481653	20060705	<--

PRIORITY APPLN. INFO.:

US 2002-364641P	P	20020314
US 2003-390544	B3	20030314
WO 2003-US7982	W	20030314

OTHER SOURCE(S): CASREACT 139:277113; MARPAT 139:277113

AB The present invention is based on the discovery that 2-deoxyribose-5-phosphate aldolase (DERA, EC 4.1.2.4) and variants thereof can be used to catalyze sequential asym. aldol reactions between a wide variety of donor and acceptor aldehydes. The reaction products typically contain at least two new stereogenic centers and can be produced in enantiomerically pure form. As such, DERA catalyzed asym. aldol chemical can be exploited to produce synthons for the synthesis of a variety of bioactive mols., e.g. epothilone A.

IT 152044-53-6P
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of atorvastatin and epothilone synthons via 2-deoxyribose-5-phosphate aldolase-catalyzed asym. aldol condensation of aldehydes)

RN 152044-53-6 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 46 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:737763 HCAPLUS
DOCUMENT NUMBER: 139:261091
TITLE: Preparation of laulimalide and epothilone derivatives as microtubule stabilizing compounds
INVENTOR(S): Ghosh, Arun K.
PATENT ASSIGNEE(S): The Board of Trustees of the University of Illinois, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076445	A2	20030918	WO 2003-US6457	20030304 <--
WO 2003076445	A3	20040108		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2478087	A1	20030918	CA 2003-2478087		20030304	<--
AU 2003216491	A1	20030922	AU 2003-216491		20030304	<--
EP 1483267	A2	20041208	EP 2003-744154		20030304	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
JP 2005521694	T	20050721	JP 2003-574661		20030304	
US 20030203929	A1	20031030	US 2003-382261		20030305	<--
US 7109235	B2	20060919				
MX 2004008630	A	20041206	MX 2004-8630		20040906	<--
PRIORITY APPLN. INFO.:			US 2002-362499P	P	20020307	
			WO 2003-US6457	W	20030304	

OTHER SOURCE(S): MARPAT 139:261091
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Laulimalide and epothilone derivs., e.g., I [R1 = H, ORa, C1-3-alkyl; R2 = C3-7-heterocyclolalkyl, C3-7-heterocyclolalkenyl, C3-7-cyclolalkyl, C3-7-cyclolalkenyl,C3-7-alkylene-ORa, ORa, C3-7-cyclolalkylene-N(Ra)2, N(Ra)2, aryl, heteroaryl; R3 = heteroaryl, aryl, C3-7-heterocyclolalkyl, C3-7-heterocyclolalkenyl; R4 = C1-4-alkyl, ORa, C3-7-cycloalkyl, C3-7-heterocyclolalkyl, aryl, heteroaryl; X, Y = CH2, O, NRa, S; Ra = H, C1-4-alkyl, C2-4-alkenyl, C2-4-alkynyl, heteroaryl, aryl; Z = (CH2)n; n = 0, 1], II, III, IV, V, VI and a pharmaceutically acceptable salt, solvate or prodrug thereof, useful as microtubule stabilizing agents, and in the treatment of cancers are disclosed. Methods of making the compds. and using the compds. as therapeutic agents in treating cancers also are disclosed. Thus, trans-desoxylaulimalide I [R1 = β-OH, R2 = R', R4 = Me, X = Y = O, Z = CH2] was prepared from (E)-R'CH:CHCH2CH[OH-(S)](CH2)2SO2Ph and {6-[(R)-Me3CSiMe2O(CH2)2]-3,6-dihydropyran-2R-yl}CH2CH[Me-(S)]CH2C(:CH2)CH2CH[OCH2OMe-(S)]CHOin 12 steps. Trans-desoxylaulimalide was tested for cytotoxicity [IC50 = 360 nM vs. human MCF-7 breast cancer cells].

IT 152044-53-6DP, Epothilone A, analogs.
152044-54-7DP, Epothilone B, analogs.
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of laulimalide and epothilone derivs. as microtubule stabilizing compds. with antitumor activity)

RN 152044-53-6 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 152044-54-7 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 47 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:719479 HCAPLUS
DOCUMENT NUMBER: 139:245815
TITLE: Preparation of derivatives of epothilones B and D for therapeutic use as antitumor agents
INVENTOR(S): Taylor, Richard E.; Chen, Yue
PATENT ASSIGNEE(S): University of Notre Dame, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074521	A1	20030912	WO 2003-US6113	20030228 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003212457	A1	20030916	AU 2003-212457	20030228 <--
US 20030176473	A1	20030918	US 2003-375100	20030228 <--
US 6900331	B2	20050531		

PRIORITY APPLN. INFO.: US 2002-360853P P 20020301
WO 2003-US6113 W 20030228

GI



I

AB (14R)- and (14S)-14-methylepothilone B I (X = O, R = α-Me, β-Me, resp.), (14S)-, and (14R)-14-methylepothilone D I (X = Z-bond, R = α-Me, β-Me, resp.) were synthesized for use in pharmaceutical compns. for treatment of cancer. The prepared

epothilones were assayed for cytotoxicity against cancer cell lines, such as human breast carcinoma MCF-7, multi-drug resistant breast carcinoma NCI/ADR, non-small cell lung carcinoma NCI-H460 and glioma SF-268.

IT 491611-01-9P, (14R)-14-Methylepothilone B 491611-02-0P , (14S)-C14-Methylepothilone B
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of derivs. of epothilones B and D for therapeutic use as anticancer agents)

RN 491611-01-9 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-2,8,8,10,12,16-hexamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,2R,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 491611-02-0 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-2,8,8,10,12,16-hexamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,2S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 48 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:697017 HCAPLUS
DOCUMENT NUMBER: 139:229340
TITLE: An oxygen-limited cultivation method for producing polyketides by myxobacteria with polyketide congener distribution modulation
INVENTOR(S): Licari, Peter J.; Julien, Bryan; Frykman, Scott; Tsuruta, Hiroko
PATENT ASSIGNEE(S): Kosan Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072730	A2	20030904	WO 2003-US5487	20030225 <--
WO 2003072730	A3	20040603		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003223190	A1	20030909	AU 2003-223190	20030225	<--
US 20040014183	A1	20040122	US 2003-376612	20030225	<--
US 7220560	B2	20070522			
EP 1485462	A2	20041215	EP 2003-719319	20030225	<--
EP 1485462	B1	20071212			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005518210	T	20050623	JP 2003-571418	20030225	
JP 4280810	B2	20090617			
CN 1639319	A	20050713	CN 2003-804528	20030225	
AT 380861	T	20071215	AT 2003-719319	20030225	
NZ 535515	A	20071221	NZ 2003-535515	20030225	
ES 2295574	T3	20080416	ES 2003-719319	20030225	
IN 2004KN01185	A	20060512	IN 2004-KN1185	20040816	
PRIORITY APPLN. INFO.:			US 2002-359821P	P 20020225	
			US 2000-724878	A2 20001128	
			WO 2003-US5487	W 20030225	

AB The present invention provides a generalized oxygen-limited cultivation method for myxobacterial strains engineered to heterologously express polyketide synthase (PKS) gene clusters under various oxygen tension conditions, modulating the polyketide congener distribution.

IT 152044-53-6P, Epothilone A 152044-54-7P, Epothilone B
RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(oxygen-limited cultivation method for producing polyketides by recombinant myxobacteria with polyketide congener distribution modulation)

RN 152044-53-6 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 152044-54-7 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L8 ANSWER 49 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:693140 HCAPLUS
DOCUMENT NUMBER: 139:191465
TITLE: Use of epothilones in the treatment of brain diseases associated with proliferative processes
INVENTOR(S): Lichtner, Rosemarie; Rotgeri, Andrea; Buchmann, Bernd; Hoffmann, Karin; Klar, Ulrich; Schwede, Wolfgang; Skuballa, Werner
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 1340498	A1	20030903	EP 2002-4745	20020301	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
CA 2477403	A1	20030912	CA 2003-2477403	20030228	<--
WO 2003074053	A1	20030912	WO 2003-EP2085	20030228	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003215618	A1	20030916	AU 2003-215618	20030228	<--
AU 2003215618	B2	20090604			
US 20040019088	A1	20040129	US 2003-375043	20030228	<--
EP 1480643	A1	20041201	EP 2003-743360	20030228	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003008154	A	20050104	BR 2003-8154	20030228	
CN 1649587	A	20050803	CN 2003-809761	20030228	
JP 2005525360	T	20050825	JP 2003-572570	20030228	
NZ 546617	A	20071221	NZ 2003-546617	20030228	
RU 2351330	C2	20090410	RU 2004-129325	20030228	
MX 2004008450	A	20050713	MX 2004-8450	20040901	
NO 2004004175	A	20041201	NO 2004-4175	20040930	<--
ZA 2004007905	A	20060426	ZA 2004-7905	20040930	

PRIORITY APPLN. INFO.:			
EP 2002-4745	A	20020301	
US 2002-361062P	P	20020301	
WO 2003-EP2085	W	20030228	

OTHER SOURCE(S): MARPAT 139:191465
AB The invention provides the use of an epothilone, which shows an average distribution coefficient between plasma and brain of 0.3-1.5 in the mouse

i.v. bolus injection assay, for the preparation of a medicament for the treatment of a brain disease associated with proliferative processes.

IT 585569-58-0 585569-62-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epothilones for treatment of brain diseases associated with proliferative processes)

RN 585569-58-0 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 10-ethyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (3S,7S,10R,11R,12S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 585569-62-6 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,12,16-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-10-propyl-, (3S,7S,10R,11R,12S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 50 OF 151 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:678602 HCAPLUS
DOCUMENT NUMBER: 139:197297
TITLE: Process for the preparation of 21-amino epothilone derivatives
INVENTOR(S): Favreau, Denis; Kant, Joydeep; Levesque, Kathia; Wang, Shaopeng; Guo, Zhengrong; James, Brian L.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070170	A2	20030828	WO 2003-US4426	20030213 <--
WO 2003070170	A3	20040708		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003211047	A1	20030909	AU 2003-211047		20030213 <--
US 20030187039	A1	20031002	US 2003-365892		20030213 <--
US 6930187	B2	20050816			
PRIORITY APPLN. INFO.:			US 2002-357554P	P	20020215
			WO 2003-US4426	W	20030213

OTHER SOURCE(S): CASREACT 139:197297; MARPAT 139:197297
GI



I

AB The present invention provides an improved one-pot conversion process for the synthesis of 21-amino epothilone derivs., such as I [R = H, alkyl; X = bond, O, S, CH2, NR1; Y = O, NH; R1 = H, alkyl, aryl, COR2, CO2R2, CONHR2, CONR2R3, SO2R3, SO2NHR2, SO2NR2R3; R2,R3 = alkyl, aryl, arylalkyl, heteroaryl; R2R3 = N, heterocycle], from 21-hydroxy epothilones. Thus, mCPBA oxidation of epothilone B provided epothilone B N-oxide, which on treatment with trifluoroacetic anhydride, lutidine and subsequently with ammonium hydroxide, afforded epothilone F (II). II was reacted with diphenylphosphoryl azide to yield 21-azido epothilone B (III), which on reaction with trimethylphosphine and ammonium hydroxide yielded 21-amino epothilone B I (R = Me; X, Y = O).

IT 219990-27-9P, Epothilone B N-oxide
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 21-amino epothilone derivs.)

RN 219990-27-9 HCAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-3-oxido-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 152044-54-7, Epothilone B
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 21-amino epothilone derivs.)
RN 152044-54-7 HCAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	146.94	333.04
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-17.22	-17.22

STN INTERNATIONAL LOGOFF AT 15:34:19 ON 07 AUG 2009